Source: International Congress 2014 – ILDs 3
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Smaldone, J. Yang, R. Condos (Stony Brook, New York, United States Of America). Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial. Eur Respir J 2014; 44: Suppl. 58, 775

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Mindfulness-based stress reduction in patients with interstitial lung disease: A pilot study Source: International Congress 2014 – ILDs 3 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study Source: International Congress 2014 – Sarcoidosis Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Live patient and partner survey on pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014